HOWL Werewolf Therapeutics Inc

$HOWL End of Q1 2027. Because the ticker will seamlessly convert to AMBX upon closing in Q1 2027, looking at current analyst twelve-month projections for HOWL provides insight into expected upside: • Consensus Average Target: Analysts hold an average consensus price target ranging between $4.00 and $5.61 per share. • High/Low Spans: The most optimistic Wall Street projections peak at $7.00 to $7.35, while the lowest baseline targets sit at $1.00 to $3.00.

$HOWL Two more weeks… when will we get the vote scheduled? What about the trial results? Hate the waiting game

$HOWL Welcome to today's latecomers. You've probably made it in just in time for Monday's news. There might be enough in this proxy to send us up 20% I really hope we can sell the CVR assets before the reverse merger. That would be a double from here. I think the reverse merger IPO is another 20% gain as institutions buy in. The ones that missed the IPO can't buy now. They have to wait for the merger.

$HOWL thinking this goes lower than it did the other day $0.86 is silliness. That was your opportunity to get in at the bottom unless you were in before the 100% plus run.

$HOWL A couple decent sized public buy blocks sitting at .93 flat all day. Will we get a late afternoon push down to fill that 30k+ order or drift back up a bit…

$HOWL Out of curiosity, will the 150M PIPE investors that get to purchase ”immediately before merger effective time” be eligible for the CVRs that are assigned ”before closing”? I really hope not as the nee investors have nothing to do with the legacy product. Has anyone been through one of these before and know the order the execution follows?